Deidra Merriwether
Analyst · Baird
Thanks, D.G. Turning to our quarterly performance. Organic daily sales, which adjust for the divestitures of Fabory and China, finished up 5.6% on a constant currency basis in the fourth quarter. Underpinned by growth in our U.S. segment and continued impressive performance in our endless assortment businesses. In the U.S., we realized strong outgrowth to the broader MRO market which contracted about 1.5% to 2% versus prior year. Our gains were driven by pandemic-related demand, which remains at elevated levels, sales to new customers and growth with midsized customers. The endless assortment model continues to deliver with 20% growth in daily sales again in the fourth quarter, while also generating improved operating margins. We remain very excited about the future of this business, and we'll discuss our plans to provide further transparency as we introduce our new GAAP reportable segments for 2021. At the total company level, margin pressure continues to be driven by pandemic-related headwinds, primarily in the U.S. segment. I will detail the pandemic mix more in a few slides. In addition, we continue to see business unit mix impact as we experienced significant growth from our endless assortment businesses. SG&A costs were favorable by $42 million year-over-year as we captured 235 basis points of SG&A leverage in the period through prudent cost controls in the U.S. and Canada, and we gained strong expense leverage in our endless assortment businesses. This resulted in Q4 operating margin at 10%, down 75 basis points from the fourth quarter last year. From a cash flow perspective, the business continues to produce robust cash flow, with operating cash flow of $336 million at 170% of net adjusted earnings, and free cash flow of $291 million. We restarted our share repurchase program in the fourth quarter and completed $500 million of repurchases in the period. Finally, we delivered strong return on invested capital at over 28% for the full year. Turning to our U.S. segment. Daily sales increased 3.7% in the quarter compared to the fourth quarter of 2019. On the product side, sales of pandemic-related products remains elevated, up 49% in the quarter, but have tapered off in the peak in the second quarter. We continue to see meaningful improvement in our non-pandemic products trends, which has improved to down 7% in the quarter, exiting the year with December at lowest decline, down 5%. We've also seen a significant uptick in new customer acquisitions month-over-month with encouraging signs of repeat buying. From a customer perspective, we see improved growth with both large and midsized customers, with the latter growing about 6% in the quarter, continuing to show signs of improvement from earlier in the year. Gross margin of 35.7% was down 290 basis points compared to the fourth quarter of 2019. The unfavorable variance in gross margin was driven most notably by pandemic-related headwinds, which accounted for nearly 90% of the GP decline. The pandemic impact was driven by continued product and customer mix and mark-to-market inventory adjustments, which D.G. outlined earlier, as well as freight-related surcharges, net of pass-through shipping charges to customers. In the second half of 2020, we started getting solid traction on price realization, which nearly offset continued cost headwinds as we exited the year. From an SG&A perspective, we gained 155 basis points of leverage with cost decreasing approximately $14 million year-over-year. The reduction was driven primarily by decreased travel expenses, lower depreciation and general operating efficiencies. Operating margin declined to 12.8% in the fourth quarter as the pandemic impact of gross margin weighted more heavily than the SG&A leverage gained. Adjusted return on invested capital was a very healthy 36.5% for the full year of 2020. Now looking at pandemic product trends. While sales of pandemic-related products decreased from the second quarter through October, continued demand for key products, including masks, gloves and cleaning supply has kept pandemic sales elevated year-over-year, and we saw this pick up again in the last few months of the year as cases spiked headed into the winter. We've also seen customers across industries prepare for the vaccine distribution maybe related but slightly different products like those required to work in refrigerated storage units. January sales remain elevated and have tapered off from Q4. On the non-pandemic side, things continue to get better. We exited the year with December down 5% and have continued to see improvement with January, roughly flat year-over-year. Looking at share gain on Slide 10. We estimate the U.S. MRO market decline between 1.5% to 2% in the fourth quarter, showing strong improvement from the mid-teens decline we saw in the second quarter. Grainger was able to capture roughly 550 basis points of outgrowth, fueled by pandemic-related sales and our growth initiatives. On a full-year basis, we estimate that we have outgrown the broader MRO market by roughly 800 basis points. This outgrowth was aided by significant pandemic-related volume, some of which, particularly in the second and third quarters, was related to large onetime orders that are unlikely to reoccur. We estimate that approximately 250 basis points of the market growth in 2020 was a result of these non-repeating pandemic transactions. Accordingly, as we move into 2021 and lap these pandemic sales spikes, we expect to see some volatility in our year-over-year share gain metric. That being said, we are confident in our ability to serve new and existing customers during these challenging times. We believe we are doing the right things in merchandising, marketing and sales effectiveness to drive repeat purchases and produce 300 to 400 basis points of sustainable outgrowth in our U.S. high-touch business. Moving to our other businesses. Organic daily sales increased 14.6% or 13% on a constant currency basis. The endless assortment business grew at an approximately 20%, with strong results in both MonotaRO and Zoro during the quarter. For our international high-touch business in both Mexico and Cromwell, we saw continued sequential improvement. However, both businesses remain impacted by pandemic-related shutdown. Overall, operating margins for other businesses were up 210 basis points. The favorability was driven by significant SG&A leverage and endless assortment, notably at Zoro, which lapped heavy investment spend in the prior year period. Zoro continues to execute the MonotaRO playbook and deliver low single-digit results for the year. Turning to Slide 12. The Canadian market has seen an overall economic slowdown during the pandemic, which has notably impacted our natural resource and export customers. Throughout the pandemic, our team in Canada has remained focused on serving new and existing customers well while also accelerating our customer diversification efforts. In Canada, daily sales decreased 3.2%, or 4.4% on a constant currency basis. Volumes in Canada reflect the pandemic-driven slowdown. However, the business continued to improve sequentially. We have positive sales growth in the month of December, and we believe the business is well suited for post-pandemic growth. Gross margin at Grainger Canada declined 1,040 basis points year-over-year. This is primarily driven by lapping significant onetime supply chain efficiencies, and to a lesser extent, the impact of pandemic-related headwinds. Cost management and the benefit of pandemic-related subsidies resulted in 315 basis points of SG&A leverage. Given the continued uncertainty surrounding the pandemic and the subsequent path of economic recovery, we will not be providing formal guidance at this time. This picture remains fluid, as does the shape of the pandemic and the customer demand for pandemic products. Similar to the last few quarters, we want to continue providing some insights into how we're thinking about the current quarter's performance. From a sales perspective, our preliminary results for January show year-over-year sales of about 9% at the total company level on a daily organic constant currency basis. While this is a strong start to the quarter, we faced more difficult comps in February and March when pandemic sales started to spike. With this, we expect daily sales to moderate and end the first quarter up between 3% and 5% organically. Note, we'll also have 1 less selling day this quarter. From a gross margin perspective, we expect GP improvement of around 50 to 100 basis points sequentially versus Q4 2020. This anticipated lift is underpinned by a slowdown in pandemic product demand, continued price cost recovery and the lapping of freight headwinds experienced in Q4 2020. On a year-over-year basis, this would imply GP will be down between 150 to 200 basis points in the quarter. With respect to SG&A, we expect costs will inch up sequentially as business activity progresses and if things like variable comp reset with the start of the new year. With this, we anticipate SG&A of between $730 million to $750 million for the first quarter of 2021. While this is up slightly versus Q4 2020, we will still be down meaningfully year-over-year. As always, we remain focused on managing near-term headwinds while continuing to invest in the business for the long term. From a capital allocation perspective, we remain committed to our balanced framework. For 2021, we anticipate investing between $225 million and $275 million back into the business. These CapEx investments include DC expansion in Japan, continued IT and KeepStock investments in the U.S., and normal levels of maintenance capital. Beyond that, we anticipate executing a similar dividend and share repurchase strategy, putting between $600 million to $700 million to work on repurchases in 2021. Although we are not providing 2021 guidance, I thought it might be helpful to provide some insights as to how a post-pandemic recovery could play out through the year. As it's the largest portion of our business and one of the most impacted by the pandemic, we have charted our U.S. segment on Slide 14 and 15, to give you some context. As we have seen continued progress on vaccine distribution and a return to near full economic activity as we enter into the second half of 2021, we would expect our results to trend back towards more normalized levels. On Slide 14, we map out year-over-year sales growth in dollars. Similar to our pandemic/non-pandemic sales chart, you can see the quarter-to-quarter sales spikes from pandemic-related products, most pronounced in the second quarter, which remained elevated through the year, and finished up $835 million or 54% in 2020. This drove pandemic product mix as a percent of total sales to 28%, a large increase compared to 19% in 2019. Conversely, non-pandemic sales were down dramatically in the second quarter and remains depressed through the balance of the year, finishing down $540 million or 8% in 2020. These trends did improve sequentially. In 2021, we expect to face lapping headwinds as pandemic sales continue to moderate from the spikes we saw last year. That being said, I think it's important to remember that more than 70% of our sales comes from non-pandemic products, and as the economy recovers and these sales rebound, it should more than offset the lapping headwinds from pandemic-related products. This will also help to normalize our product mix back towards pre-COVID levels. Accordingly, we would expect to see year-over-year growth in 2021, but the magnitude will be determined by the pace of the economic recovery. Related to gross profit margin, as product mix trends towards pre-pandemic levels, we would expect to see improved GP rates throughout the year. This includes sequential improvement from Q4 2020, beginning in Q1 2021. We expect to exit the year with U.S. GP rates as high or higher than Q1 2020 levels. I want to reiterate, while this commentary relates to the U.S. business, we showcased it because it represents more than 70% of the total company results and was the most heavily impacted by the pandemic. With that, I will turn it back over to D.G.